Exem Foam Kit generics — when can they launch?
Exem Foam Kit (AIR POLYMER-TYPE A) · Giskit · 3 active US patents · 0 expired
Where Exem Foam Kit sits in the generic timeline
Mid-term cliff: earliest active US patent for Exem Foam Kit expires in 2030 (~4 years). Generic developers typically begin ANDA bioequivalence studies 3-4 years ahead of this date. Paragraph IV filings + Hatch-Waxman 30-month stays may shift the effective entry by another 18-36 months.
Under US Hatch-Waxman, a generic enters via an ANDA (Abbreviated New Drug Application) and may file with one of four Paragraph IV certifications attacking the brand's listed patents. If the brand sues within 45 days, a 30-month FDA approval stay is triggered. First Para IV filer typically gets 180-day market exclusivity.
Patent estate by type — active patents
Method-of-use patents only carve out specific indications; generics can launch with a "skinny label" omitting those uses. Composition-of-matter patents block the molecule itself.
- Method of Use — 2 patents
- Formulation — 1 patent
FDA U-codes carved out by Exem Foam Kit patents
Method-of-use patents are listed against specific FDA Patent Use Codes ("U-codes") representing carved-out indications. Generics can launch with a label that omits these uses.
| U-code | Description |
|---|---|
U-2663 | (no description) |
Sample patent estate
Showing 3 of 3 active US patents. View full estate on the Exem Foam Kit drug page →
-
This patent protects a foamed aqueous composition for medical imaging of body cavities, particularly suitable for patency tests and fallopian tube sterilization checks.USPTO title: Composition and method for medical imaging of body cavities
-
This patent protects a foamed aqueous composition containing cellulose for use in medical imaging of body cavities.USPTO title: Composition and method for medical imaging of body cavities
-
This patent protects a foamed aqueous composition containing cellulose for medical imaging of body cavities.USPTO title: Composition and method for medical imaging of body cavities
Sources
- FDA Orange Book — patents listed against Exem Foam Kit (NDA filed 2019)
- Exem Foam Kit drug profile — full patent estate, indications, clinical trials, pricing
- Giskit patent portfolio
- Patent cliff 2030 — every drug losing US exclusivity that year
Patent term extensions (PTR, pediatric exclusivity), Hatch-Waxman 30-month stays, and FDA regulatory exclusivity (NCE/ODE/PED) may shift the effective generic entry date. Not legal advice.
Get generic entry alerts
Free Pharma CI alerts on Exem Foam Kit — get notified the moment an ANDA Paragraph IV certification is filed, a 30-month stay is triggered, or a generic launches. First 2 drugs free.
Subscribe free →